Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, will present at the 27th Annual H.C. Wainwright Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 PM ET at the Lotte New York Palace Hotel.
The company has uploaded an updated corporate presentation to their website's investor section. Management will be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.
Details
News Market Reaction – SLXN
On Sep 2, the day this news came out, SLXN closed 1.47% below the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City.
Silexion's company presentation will take place on Tuesday, September 10, 2025, at 2:00 PM ET. An updated company presentation has been posted to Silexion's website in the Presentation & Events section of the Company’s investor site.
The Silexion management team will be available for in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with Silexion through their H.C. Wainwright representative or e-mail meetings@hcwco.com
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Contacts
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.